CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. - Wikidata - awgldk - TriplyDB

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

http://www.wikidata.org/entity/Q34579138

about

One-step enzymatic modification of the cell surface redirects cellular cytotoxicity and parasite tropism.Mechanisms of action of therapeutic antibodies for cancer A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.Bispecific antibodies for cancer therapy.Development and prospects for bispecific antibody-based therapeutics in cancer and other applications.Emerging drugs for diffuse large B-cell lymphoma.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats.Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Development and characterization of a novel luciferase based cytotoxicity assay.Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy Emerging classes of armed antibody therapeutics against cancer Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents

P2860

Q27339549-4D93CDC5-916D-4CFF-8DA8-22B2ACFD8ECF Q28385366-F18B0FFE-C62F-4E67-9E0F-66EAB98C4B80 Q30564779-4A787110-8D5E-4151-9F20-92F55B112ADE Q34005156-86D49E7D-24D8-4A29-A4E2-CDD12E3247EC Q34116916-57A51989-57E2-4E35-A91F-05C3EC67C425 Q34503084-BDD9D8BB-D093-42A9-BB1A-52AFA8E8C11F Q34550963-D62DC78F-E18A-49F4-83EB-A24325438491 Q34598149-D35A8492-CC26-4874-B3AF-BB9882FA1389 Q36022539-994F543F-B007-4E0C-A449-6365DCB4C1FD Q36211422-92687D5D-A7A4-4E20-A0D4-DCA12C6E34A8 Q36700470-6D3CCBF9-E005-4374-B92A-2A891F62CAFE Q37220750-51EF1083-F49C-41D9-981D-FBFFD6EA9245 Q37773263-D661A8AF-E234-4C96-9A11-BF0667629C49 Q38090680-5F3D01DE-7233-4839-8E7A-D72C332601FF Q38344404-EB3FB7C9-D3A3-4B6B-A279-2E91810FA922 Q38364462-37ADACB4-972F-4CD6-8DCE-3EABCDDCB9F2 Q38972314-8075D297-D7FB-43FF-8807-151E70C6E4A6 Q39548378-1F27ACD3-2EA2-45C3-84C5-A57B9B980D74 Q39931512-EDA57A82-F956-4892-8455-76A4E06D8411 Q40043393-3CEC0F8A-0284-46C5-AB71-5049D04B7813 Q41590699-DD7987D2-8DF5-4F2E-AA8D-B84734D047A1 Q42153659-23F196F0-C41E-411A-8CE5-3F2434BBC730 Q44139242-75BE78D1-7186-4B7D-B6EC-F733B9FF5F3D Q47138591-9E1C0E3B-C916-45DD-8730-E47A1AC49DBA Q47570404-DA03C619-F402-4208-AFD1-50630C637E44 Q48276267-811D32B4-5106-4738-80BD-29E567057D53 Q49260956-DE7131A5-B096-4A7B-8F0B-2DBCF7B12DE7 Q56889651-4CAAC852-057B-4366-9D7E-86E9D66BE05C Q57911948-4EB90F61-8D5A-470B-B6C4-2453BBFACC8D Q58724935-E5D1BBCC-699A-4AF8-9581-1956331DED18 Q58726545-D2051BEC-F24D-4BF5-AA0D-25891182592F

P2860

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

http://www.wikidata.org/entity/Q34579138

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@ast

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@en

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@nl

type

label

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@ast

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@en

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@nl

prefLabel

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@ast

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@en

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@nl

P1433

Q34579138-99482DE3-A036-4684-8422-758E816579B4

P1476

Q34579138-456ABE9F-06C4-4FE5-8117-79F66B726481

P2093

Q34579138-07685D94-B27D-4443-B9F8-37ABFD48BEF6

Q34579138-593266A1-3EF9-4CAF-AE4A-C7250FE7A6C2

Q34579138-72277870-C9CB-4B4A-AB9B-A695496DAC26

Q34579138-9322BFBF-377B-4061-BBBE-186B0ECA2308

Q34579138-B9CC7EE3-21D8-45ED-8438-0F049019C3CB

Q34579138-C98A0F28-7698-4510-9639-42CB6431DE02

Q34579138-CC07B16D-4B6B-4A48-97E9-3E9940D0B9DF

Q34579138-DF200529-D25A-4968-A838-87AC4373E167

Q34579138-FB54FB08-4FFC-42BB-8D83-7294494D7C50

P304

Q34579138-15F05150-0473-4D6F-8C24-9164CC24DBC1

P31

Q34579138-F3E55B41-33AC-4293-81D6-EF37F9E008E8

P356

Q34579138-938756FF-F220-4DFE-9443-DDF4E9CEEA55

P433

Q34579138-0A0BA21B-0093-445D-9D48-3AF2DFC9DA5F

P478

Q34579138-0CAB5D98-00DA-49DE-852B-1FA0DEE6BB1F

P577

Q34579138-CB3C2A36-9B76-4582-83ED-1B0613E46009

P698

Q34579138-A05F84EB-86E8-42CA-8E04-B30C09E57B63

P921

Q34579138-697B22AD-ED61-4063-9ADB-A5E16549B5A5

P356

J.MOLIMM.2006.09.032

P1433

Molecular Immunology

P1476

CD19-/CD3-bispecific antibody ...... o redirected tumor cell lysis.

@en

P2093

Doris Rau

http://www.w3.org/2001/XMLSchema#string

Klaus Brischwein

http://www.w3.org/2001/XMLSchema#string

Michael Mølhøj

http://www.w3.org/2001/XMLSchema#string

Mirnaalini Sriskandarajah

http://www.w3.org/2001/XMLSchema#string

Patrick A Baeuerle

http://www.w3.org/2001/XMLSchema#string

Patrick Hoffmann

http://www.w3.org/2001/XMLSchema#string

Peter Kufer

http://www.w3.org/2001/XMLSchema#string

Robert Hofmeister

http://www.w3.org/2001/XMLSchema#string

Sandrine Crommer

http://www.w3.org/2001/XMLSchema#string

P304

1935-1943

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLIMM.2006.09.032

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17083975

http://www.w3.org/2001/XMLSchema#string

P921